Tabula Rasa HealthCare (TRHC) Coverage Initiated by Analysts at Oppenheimer

Oppenheimer initiated coverage on shares of Tabula Rasa HealthCare (NASDAQ:TRHC) in a research note issued to investors on Monday morning. The brokerage issued an outperform rating and a $35.00 price objective on the stock.

Several other equities research analysts also recently commented on the stock. Zacks Investment Research downgraded shares of Tabula Rasa HealthCare from a strong-buy rating to a hold rating in a research report on Friday, November 10th. BidaskClub downgraded shares of Tabula Rasa HealthCare from a strong-buy rating to a buy rating in a research report on Wednesday, December 6th. First Analysis began coverage on shares of Tabula Rasa HealthCare in a research report on Wednesday, November 1st. They issued an overweight rating and a $41.00 price target for the company. William Blair began coverage on shares of Tabula Rasa HealthCare in a research report on Monday, December 11th. They issued an outperform rating for the company. Finally, Piper Jaffray Companies reiterated an overweight rating and issued a $35.00 price objective on shares of Tabula Rasa HealthCare in a research note on Tuesday, November 7th. They noted that the move was a valuation call. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $29.00.

Shares of Tabula Rasa HealthCare (NASDAQ TRHC) opened at $29.50 on Monday. Tabula Rasa HealthCare has a one year low of $11.59 and a one year high of $36.80. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.73 and a quick ratio of 0.66.

Tabula Rasa HealthCare (NASDAQ:TRHC) last released its earnings results on Monday, November 6th. The company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.06 by $0.02. Tabula Rasa HealthCare had a negative net margin of 2.27% and a negative return on equity of 5.58%. The business had revenue of $33.27 million during the quarter, compared to analyst estimates of $31.76 million. During the same period in the prior year, the business earned $0.06 earnings per share. The business’s quarterly revenue was up 37.6% on a year-over-year basis. equities research analysts forecast that Tabula Rasa HealthCare will post 0.05 earnings per share for the current fiscal year.

In other news, insider Orsula V. Knowlton sold 8,000 shares of the firm’s stock in a transaction dated Wednesday, October 18th. The shares were sold at an average price of $26.68, for a total transaction of $213,440.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bruce Luehrs sold 269,000 shares of the firm’s stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $25.85, for a total transaction of $6,953,650.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,099,180 shares of company stock worth $28,435,203. 45.80% of the stock is currently owned by company insiders.

Several large investors have recently added to or reduced their stakes in TRHC. TIAA CREF Investment Management LLC lifted its holdings in Tabula Rasa HealthCare by 108.5% during the 1st quarter. TIAA CREF Investment Management LLC now owns 8,131 shares of the company’s stock valued at $110,000 after purchasing an additional 4,232 shares during the last quarter. Financial Consulate Inc. bought a new position in Tabula Rasa HealthCare during the 3rd quarter valued at about $222,000. Rhumbline Advisers bought a new position in Tabula Rasa HealthCare during the 3rd quarter valued at about $253,000. California Public Employees Retirement System bought a new position in Tabula Rasa HealthCare during the 3rd quarter valued at about $254,000. Finally, New York State Common Retirement Fund lifted its holdings in Tabula Rasa HealthCare by 257.0% during the 2nd quarter. New York State Common Retirement Fund now owns 10,000 shares of the company’s stock valued at $151,000 after purchasing an additional 7,199 shares during the last quarter. 31.85% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.com-unik.info/2017/12/19/tabula-rasa-healthcare-trhc-coverage-initiated-by-analysts-at-oppenheimer.html.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

What are top analysts saying about Tabula Rasa HealthCare? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Tabula Rasa HealthCare and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit